Soligenix Aktie Logo
US8342236044

Soligenix Aktie

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Kaufen
  4
Halten
  3
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

    PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.» Mehr auf globenewswire.com


  • Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

    PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.» Mehr auf prnewswire.com


  • Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

    Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL).» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Soligenix Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 0,00
(EUR)März 2025
YOY
Umsatz0,00100,00%
Bruttoeinkommen0,00100,00%
Nettoeinkommen0,00100,00%
EBITDA3,06 Mio72,08%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+5,52 Mio
Anzahl Aktien
3,26 Mio
52 Wochen-Hoch/Tief
+13,00 - +1,47
DividendenNein
Beta
1,97
KGV (PE Ratio)
0,93
KGWV (PEG Ratio)
0,03
KBV (PB Ratio)
+1,63
KUV (PS Ratio)
+2.690,09

Unternehmensprofil

Name
Soligenix Aktie
CEO
Dr. Christopher J. Schaber Ph.D.
Mitarbeiter14

Assets entdecken

Shareholder von Soligenix Aktie investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr